Year-Long trial tests new schizophrenia medication
Disease control
Not yet recruiting
This study will test the long-term safety and effectiveness of the medication ML-007C-MA in adults with schizophrenia. About 500 participants will take the medication for 52 weeks while researchers monitor side effects and how well it controls symptoms. The goal is to see if this…
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC